TACE联合RFA治疗原发性肝细胞癌预后多因素分析

目的探讨TACE联合RFA治疗原发性肝癌（HCC）预后的主要影响因素。方法回顾性分析86例经治疗的HCC患者的临床和随访资料,观察远期疗效,应用Kaplan-Meier法计算累积生存率,绘制生存曲线,对可能影响预后的16项因素行Cox多因素回归分析。结果本组患者6、12、24、36个月生存率分别为94.20%、89.40%、65.80%、49.70%,平均生存时间为（42.98±3.80）个月。多因素分析显示影响预后因素包括肝功能Child分级、Barcelona分期、肿瘤最大直径及治疗效果。结论 TACE联合RFA是治疗HCC的有效方法,其中患者肝功能Child分级、肿瘤Barcelona分期、肿瘤大小是影响预后的危险因素,治疗效果是影响预后的保护性因素。

Analysis of impact factors of prognosis for patients with hepatocellular carcinoma after TACE combined with radiofrequency ablation

Objective To investigate impact factors of TACE combined with radiofrequency ablation (RFA) for prognosis in patients with hepatocellular carcinoma (HCC). Methods Clinic treatment and following data of 86 cases of HCC treated with TACE combined with RFA were analyzed retrospectively to observe treatment effect. Kaplan-Meier way was used to count the survival rate and generate the survival curve map. Cox regression analysis model was used to analyze 16 factors which may affect the prognosis. Results The survival rates at 6, 12, 24, 36 months was 94.20%, 89.40%, 65.80% and 49.70%, respectively, mean time was (42.98±3.80) months. Multivariable analysis revealed significant prognostic factors including liver function, Barcelona clinic cancer stage, tumor sizes and treatment effect. Conclusion Liver function, Barcelona clinic cancer stage and tumor sizes are the risk prognostic factors, and treatment effect is a protective factor for HCC patients after TACE combined with RFA.